Supplemental Figure 1



(A) IL-6, TNF-α, and IL-12/23p40 concentrations measured by ELISA in the supernatants (SN) of BMDM treated with DMSO, the ER stress inducer tunicamycin (TM), or thapsigargin (TG) followed by the indicated TLR agonists.
(B) IL-23 concentration in the SN of BMDM treated with DMSO or TM followed by indicated concentration of LPS.
(C) Modulation of cell viability assessed by MTT assay in response to ER stress and TLR agonists.
(D) Effects of LPS stimulation before or after TM in terms of IL-1β production.
(E) Immunoblots of SN and cellular extracts (XT) from WT BMDM treated with ER stress inducers and LPS or alternatively with LPS/ATP.
(F) Immunoblots of SN from WT or mentioned KO BMDM in response to LPS/ATP stimulation.
(G) Densitometry analysis of pro- and mature IL-1β from *Ripk3+/– Casp8+/–*, *Ripk3–/– Casp8+/–*, and *Ripk3–/– Casp8–/–* BMDM treated with ER stress inducers and LPS.
(H) Fold increase of pro-IL1β in response to TG/LPS as compared to DMSO/LPS.

Supplemental Figure 2











F

		Fig.1B									Fig.2A									Fig.2B					
		4h			4h + 18h Medium			4h + 18h LPS			WT			ASC-/-			Casp1/11-/-			Ripk3 +/- Casp8 +/-			Ripk3 -/- Casp8 +/-			Ripk3 -/- Casp8 -/-		
		DMSO	TM	TG	DMSO	TM	TG	DMSO	TM	TG	DMSO	TM	TG	DMSO	TM	TG	DMSO	TM	TG	DMSO	TM	TG	DMSO	TM	TG	DMSO	TM	TG
Supernatant (Arbitrary unit)	Il1β	0.6	0.8	1.0	1.3	5.7	3.2	1.6	22.0	14.1	0.8	13.2	14.0	1.3	9.9	13.7	0.9	0.5	5.6	0.5	19.7	19.3	1.8	7.3	9.8	0.6	0.3	0.9
	Casp1	0.3	0.4	0.9	1.5	3.7	4.2	2.4	23.6	12.1	0.8	20.3	8.1	0.7	3.9	1.8	0.4	0.3	0.2	0.2	20.2	2.2	0.5	15.7	3.5	0.5	0.5	0.5
	Casp8										0.4	13.9	4.1	0.4	8.2	3.6	0.1	1.5	2.0	1.0	12.0	14.2	1.0	17.8	17.6	0.6	0.3	0.2
Cell extract (fold over GAPDH)	ProIL1β	0.2 *(0.08)	0.3 *(0.09)	0.2 *(0.08)	0.2 *(0.08)	0.1 *(0.05)	0.2 *(0.06)	0.6 *(0.28)	1.1 *(0.73)	2.2 *(1.98)	0.4 (0.4)	0.6 (0.6)	1.2 *(1)	1 *(0.9)	1 *(0.8)	1 *(1)	0.6 *(0.5)	0.3 *(0.3)	2 *(1.6)	3.1 *(1)	1.8 *(2.2)	2.5 *(3.1)	0.5 *(0.3)	0.6 *(0.7)	1.6 *(2)	0.2 *(0.2)	0.5 *(0.5)	1.3 *(1.6)
	ProCaspase1	0.8	1.1	0.8	1.3	0.8	0.8	0.9	0.7	0.8	1.1	1.0	1.2	1.1	1.1	1.3	0.1	0.0	0.0	2.7 *(2.7)	2.1 *(1.8)	2.2 *(2.9)	2.2 *(3)	1.9 *(2.6)	1.9 *(2.9)	2.3 *(3.5)	1.8 *(2.6)	1.8 *(2.8)
	ProCaspase8										0.7	1.0	1.2	1.1	1.4	1.3	1.0	0.8	1.4	1.0	3.1	2.1	0.6	1.8	1.1	0.1	0.1	0.1
	CHOP	0.0	0.1	0.8	0.2	1.6	0.9	1.0	1.5	0.4																		
	Bip	0.2	0.3	0.3	0.2	1.0	0.5	0.3	0.8	0.8																		

		Fig.3									Supl. Fig.1E				Supl. Fig.2B							Supl. Fig.2C								
		WT			MyD88-/-			Trif-/-			WT				WT			Xbp-1 Mx1 CRE			WT	Xbp-1 Mx1 CRE		WT	Chop -/-		WT	Chop -/-		WT	Chop -/-	
		DMSO	TM	TG	DMSO	TM	TG	DMSO	TM	TG	DMSO	TM	TG	LPS/ATP	DMSO	TM	TG	DMSO	TM	TG	LPS/ATP	DMSO			TM			TG			LPS/ATP	
Supernatant (Arbitrary unit)	Il1β	2.6	18.7	14.4	2.0	1.6	0.5	0.2	0.5	0.6	0.9	13.6	24.8	19.3	0.5	8.3	12.3	0.9	4.2	13.9	14.3	19.1	0.5	1.0	6.0	5.5	3.6	2.3	11.6	9.9
	Casp1	1.5	19.2	4.0	1.8	14.5	7.9	0.7	0.2	0.1	0.1	9.1	11.1	19.6	0.5	8.4	4.8	0.5	4.4	5.2	8.1	6.9	0.2	1.1	5.5	9.9	1.8	2.2	8.0	10.1
	Casp8	0.5	18.4	8.9	0.4	13.9	9.2	0.3	0.3	0.4	0.2	10.9	15.2	1.1	0.3	9.4	5.4	0.5	4.5	7.6	0.4	0.3	0.4	0.7	6.5	4.5	2.9	2.7	0.7	1.1
Cell extract (fold over GAPDH)	ProIL1β	1.5	1.4	1.6	0.0	0.0	0.0	1.0	0.7	2.3					0.5	0.3	1.3	0.8	0.4	1.6	0.9	1.1	0.2	0.4	1.0	1.2	0.6	0.5	0.6	0.6
	ProCaspase1	0.7	0.6	0.8	1.4	1.2	1.2	1.1	0.9	1.2	1.4	1.9	1.8	1.0	0.6	0.7	0.8	1.5	0.8	1.1	0.7	0.8	0.9	1.0	0.9	0.8	0.8	0.9	0.6	0.7
	ProCaspase8	2.3	1.2	2.0	2.5	0.7	1.3	2.7	2.2	2.4	0.6	1.0	0.8	0.7	0.4	0.4	0.4	1.1	0.5	0.9	0.4	0.4								

		Supl. Fig.1E									Supl. Fig.2A									Supl. Fig.2D					
		WT	ASC-/-	Casp 1/11-/-	WT	MyD88 -/-	Trif -/-	Ripk3 +/- Casp8 +/-	Ripk3 -/- Casp8 +/-	Ripk3 -/- Casp8 -/-	WT			Fas-/-			Tnf -/-			WT			Tlr4 -/-		
		LPS ATP									DMSO	TM	TG	DMSO	TM	TG	DMSO	TM	TG	DMSO	TM	TG	DMSO	TM	TG
Supernatant (Arbitrary unit)	Il1β	7.3	0.3	0.2	8.1	0.7	3.5	8.7	6.7	4.0	0.7	6.1	9.8	2.5	7.3	8.6	1.0	5.1	4.7	0.6	25.8	13.6	0.6	2.5	0.6
	Casp1	12.2	0.4	0.2	8.8	0.8	6.0	5.6	5.4	14.0	0.5	9.6	5.4	1.4	6.5	3.3	1.5	5.2	1.3	0.6	34.3	12.1	4.6	5.4	2.7
	Casp8	2.3	0.0	0.0	1.2	0.8	1.7	0.5	0.6	0.3	0.6	17.6	13.7	1.2	11.5	8.0	0.9	12.0	5.9	0.7	31.9	14.5	0.7	5.4	0.8

Increasing expression

Immunoblots of WT, *Fas–/–* and *Tnf–/–* (A), *Xbp1F/F* and *Xbp1F/F Mx1-Cre* (B), *chop–/–* (C) or *Tlr4–/–* (D) BMDM treated with ER stress inducers and LPS.
(E) Proposed model of LPS mediated IL-1β production in the context of ER stress.
(F) Quantification of all presented blots using ImageJ. Numbers in parentheses were obtained from less exposed films